BioNxt Solutions Company Description

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland.

The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; and BNT24004 for the treatment of semaglutide.

It also offers diagnostic screening tests; new active pharmaceutical production and evaluation, including precision transdermal and oral dissolvable drug formulations; infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications.

The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022.

BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

BioNxt Solutions Inc.

Country	Canada
Founded	2017
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
CEO	Wolfgang Probst

Contact Details

Address: 1928 Linden Road Vancouver, British Columbia V6M 1E7 Canada
Phone	780 818 6422
Website	bionxt.com

Stock Details

Ticker Symbol	BNXT
Exchange	Canadian Securities Exchange
Fiscal Year	January - December
Reporting Currency	CAD
ISIN Number	CA0909741062
SIC Code	2834

Key Executives

Name	Position
Wolfgang Probst	Co-Founder, Interim Chief Executive Officer and Director
Hugh A. D. Rogers B.Sc., LL.B	Co-Founder and Director
Dr. Raimar Lobenberg Ph.D.	Co-Founder and Director
Patrick Joseph Meagher C.A., CPA, CA, CPA	Chief Financial Officer, Corporate Secretary and Director
Dr. Florian A. Sahr	Head of Project Management
Dr. Wolfgang Wagner	Head of Research and Development